Blood and tissue tests to predict how tumors respond to radiation
Part of Cancer clinical trials.
This study looks at tumor tissue and/or blood “biomarkers” to help predict whether a solid tumor will respond well to radiation therapy. It may help doctors choose more effective treatments in the future, and it may guide your care during radiotherapy if you qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid-tumor diagnosis based on pathology (biopsy or surgery result).
- Your tumor is reachable for biopsy during your radiation treatment, or you can provide a tumor sample from surgery.
- You are able and willing to sign the study’s consent form before starting any study steps.
- You do not have a history of autoimmune disease.
- You have not had immunotherapy before, and you will not receive immunotherapy during your radiation treatment.
- You do not need a prior radiation plan that overlaps with the new radiation fields, and biopsy is safe for you (no high bleeding risk).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects tumor tissue and related blood tests from people who already need a biopsy or surgery as part of their usual care. Researchers use the samples to learn what drives the tumor and how the tumor environment may affect treatment, which could help develop future therapies.
This trial is testing whether a protein called CHI3L1 in your blood can help predict how well tumors will respond to radiation therapy. It is open to people with several types of cancer who are in good overall health.
This study looks for “biomarkers,” or measurable signs (often from blood or samples), that may show which cancers respond better to radiation therapy. It may help doctors choose radiation treatment more precisely, especially for people who had significant side effects before.
This study looks at how a tumor’s immune system responds when you receive radiotherapy. It involves taking a planned pre-treatment biopsy so researchers can study immune and tumor changes and see if radiotherapy affects them.
This study collects blood and may also use existing tumor tissue to help develop a liquid biopsy blood test for people with solid (non-blood) cancers. You may qualify if you have a current cancer with tumor in the body and can provide blood samples at set visits.
This study looks at the genetic information (DNA) from your blood and from saved tumor tissue to better understand certain cancers, especially rare cancers with a poor outlook. It may help researchers learn why these cancers behave the way they do and guide future treatments.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.